RBI 1000
Alternative Names: RBI-1000Latest Information Update: 21 Apr 2023
At a glance
- Originator Immunomic Therapeutics; Replicate Bioscience
- Developer Replicate Bioscience
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 19 Apr 2023 Pharmacodynamics data from a preclinical study in Breast cancer released by Replicate Bioscience
- 17 Mar 2023 Pharmacodynamics data from a preclinical study released by Replicate Bioscience
- 26 Jun 2022 Preclinical trials in Breast cancer in USA (IM) (Replicate Bioscience pipeline, June 2022)